Dipen M Maru, M.D.

Peer-Reviewed Articles

1. Goltsov, A, Maru, DM, Katkhuda, R, Duose, D, Luthra, R, Correa, AM, Wang, F, Futreal, A, Hofstetter, WL. ANPEP/CD13 Expression as a Marker of Lymphovascular Invasion and Survival in Esophageal Adenocarcinoma. Annals of Thoracic Surgery 118(1):241-251, 2024. e-Pub 2024. PMID: 37806335.
2. Mitchell KG, Bayley EM, Ikoma N, Antonoff MB, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Erasmus JJ, Weston BR, Ajani JA, Badgwell BD, Hofstetter WL. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg 117(2):320-326, 2024. e-Pub 2023. PMID: 37080372.
3. Lima, CF, Tamegnon, A, Rodriguez, S, Maru, DM, Martin, P, Cooper, Z, Rodriguez Canales, J, Parra Cuentas, ER. Exploring the Expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence. Pathobiology 91(3):205-218, 2023. e-Pub 2023. PMID: 37926083.
4. Maki H, Haddad A, Ayabe RI, Lendoire M, Khanduri I, Maru DM, Vauthey JN. TP53 Alteration and Its Effect on Pathologic Response Are Associated with Survival after Resection of Colorectal Liver Metastases. J Gastrointest Surg 27(11):2597-2600, 2023. e-Pub 2023. PMID: 37553514.
5. Rolfe C, Ozmen A, Maru D. Beginning your hearing health journey with the online hearing test. BJGP Open. e-Pub 2023. PMID: 37295797.
6. Stigwood A, Maru D, Hadley E, Molloy A, Benneyworth R, Owolabi B. Responding to the systemic inequalities experienced by ethnic minority-led GP providers. BMJ Lead 7(2):137-139, 2023. e-Pub 2023. PMID: 37200181.
7. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
8. Jiao J, Sanchez JI, Saldarriaga OA, Solis LM, Tweardy DJ, Maru DM, Stevenson HL, Beretta L. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Rep 5(2):100628, 2023. e-Pub 2023. PMID: 36687470.
9. Khanduri I, Maru DM, Parra ER. Exploratory study of macrophage polarization and spatial distribution in colorectal cancer liver metastasis: a pilot study. Front Immunol 14:1223864, 2023. e-Pub 2023. PMID: 37637998.
10. Philpott CM, Espehana A, Garden M, Ta N, Gadi N, Kumaresan K, Maru D, Stafford LD, Bleasdale N, Boak D. Establishing UK research priorities in smell and taste disorders: A James Lind alliance priority setting partnership. Clin Otolaryngol 48(1):17-24, 2023. e-Pub 2023. PMID: 36148690.
11. Tiwari A, Thapa A, Choudhury N, Khatri R, Sapkota S, Wu WJ, Halliday S, Citrin D, Schwarz R, Maru D, Rayamazi HJ, Paudel R, Bhatt LD, Bhandari V, Marasini N, Khadka S, Bogati B, Saud S, Kshetri YKB, Bhatta A, Magar KR, Shrestha R, Kafle R, Poudel R, Gautam S, Basnett I, Shrestha GN, Nirola I, Adhikari S, Thapa P, Kunwar L, Maru S. A Type II hybrid effectiveness-implementation study of an integrated CHW intervention to address maternal healthcare in rural Nepal. PLOS Glob Public Health 3(1):e0001512, 2023. e-Pub 2023. PMID: 36963046.
12. Gunther, J, Chadha, AS, Guha, S, Raju, GS, Maru, DM, Munsell, M, Jiang, Y, Yang, P, Felix, E, Clemons, M, Mathew, GG, Singh, PK, Skibber, JM, Rodriguez-Bigas, MA, Chang, GJ, Eng, C, Delclos, ME, Crane, C, Das, P, Krishnan, S. A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. Journal of Gastrointestinal Oncology 13(6):2938-2950, 2022. e-Pub 2022. PMID: 36636059.
13. Zhou N, Hofstetter WL, Working Group ESCC, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg 114(6):2032-2040, 2022. e-Pub 2022. PMID: 34883083.
14. Davis, JS, Chavez, JC, Kok, M, San Miguel, Y, Lee, HY, Henderson, H, Overman, MJ, Morris, VK, Kee, BK, Fogelman, D, Advani, S, Johnson, B, Parseghian, C, Shen, JY, Dasari, NV, Shaw, KR, Vilar Sanchez, E, Raghav, KS, Shureiqi, I, Wolff, RA, Meric-Bernstam, F, Maru, DM, Menter, DG, Kopetz, S, Chang, S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin with Survival from Stage IV Colorectal Cancer. JAMA Network Open 5(10):E2236357, 2022. e-Pub 2022. PMID: 36239938.
15. Chun YS, Passot G, Nishioka Y, Katkhuda R, Arvide EM, Benzerdjeb N, Lopez J, Kopetz SE, Maru DM, Vauthey JN. Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery. J Am Coll Surg 235(1):8-16, 2022. e-Pub 2022. PMID: 35703957.
16. Rha SY, Ku GY, Kim HS, Chung HC, Amlashi FG, Maru DM, Fein CA, Tang LH, Zhou W, Wu T, Peter SA, Kelsen DP, Ajani JA. PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Future Oncol 18(21):2623-2634, 2022. e-Pub 2022. PMID: 35616013.
17. Bostock IC, Zhou N, Antonoff MB, Murphy MB, Lin S, Maru D, Mehran R, Rajaram R, Rice D, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Hofstetter W. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus 35(4), 2022. e-Pub 2022. PMID: 34897440.
18. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
19. Corsini EM, Foo WC, Mitchell KG, Zhou N, Maru DM, Ajani JA, Hofstetter WL, Working Group EA, Correa AM, Antonoff MB, Lin SH, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg 162(5):1404-1412.e2, 2021. e-Pub 2021. PMID: 33010880.
20. Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba II, Gupta S, Lee JJ, Overman MJ, Tam AL. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol 5(1):94, 2021. e-Pub 2021. PMID: 34707215.
21. Chowdhury S, Hofree M, Lin K, Maru D, Kopetz S, Shen JP. Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638407.
22. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147.e1, 2021. e-Pub 2021. PMID: 33229221.
23. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
24. Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Lin SH, Ajani JA, Hofstetter WL. Modified En bloc Esophagectomy Compared to Standard Resection after Neoadjuvant Chemoradiation. Ann Thorac Surg 111(4):1133-1140, 2021. e-Pub 2021. PMID: 32857997.
25. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg 273(4):751-757, 2021. e-Pub 2021. PMID: 31188215.
26. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam GC, Advani SM, Katkhuda R, Verma A, Lam M, Willis J, Shen JP, Morris J, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer. Clin Cancer Res 27(6):1663-1670, 2021. e-Pub 2021. PMID: 33414133.
27. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol 39(4):285-294, 2021. e-Pub 2021. PMID: 33356422.
28. Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res 27(1):120-130, 2021. e-Pub 2021. PMID: 33109741.
29. Yamashita S, Chun YS, Kopetz SE, Maru D, Conrad C, Aloia TA, Vauthey JN. APC and PIK3CA Mutational cooperativity predicts pathologic response and survival in patients undergoing resection for colorectal liver metastases. Ann Surg 272(6):1080-1085, 2020. e-Pub 2020. PMID: 28379870.
30. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Murphy MAB, Maru DM, Weston B, Lee JH, Rogers JE, Trail A, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Das P, Hofstetter WL, Badgwell BD, Ajani JA. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer 23(5):904-912, 2020. e-Pub 2020. PMID: 32347396.
31. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg 272(2):311-318, 2020. e-Pub 2020. PMID: 32675544.
32. Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus 33(3), 2020. e-Pub 2020. PMID: 31313820.
33. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
34. Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore) 99(9):e19295, 2020. e-Pub 2020. PMID: 32118743.
35. Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, Kurtz DM, Jin M, Schroers-Martin J, Stehr H, Liu CL, Hui AB, Patel V, Maru D, Lin SH, Alizadeh AA, Diehn M. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology 158(3):494-505.e6, 2020. e-Pub 2020. PMID: 31711920.
36. Nelson DB, Mitchell KG, Weston BR, Betancourt S, Maru D, Rice DC, Mehran RJ, Sepesi B, Antonoff MB, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Blum M, Hofstetter WL. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer?. Dis Esophagus 32(10):1-6, 2019. e-Pub 2019. PMID: 30888418.
37. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech 12(12), 2019. e-Pub 2019. PMID: 31732509.
38. Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer 7(1):329, 2019. e-Pub 2019. PMID: 31779702.
39. Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Weston BR, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Swisher SG, Sepesi B, Walsh GL, Correa AM, Das P, Blum MA, Badgwell BD, Hofstetter WL. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg 108(3):845-851, 2019. e-Pub 2019. PMID: 31102632.
40. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 10(45):4703-4718, 2019. e-Pub 2019. PMID: 31384397.
41. Xi M, Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier CL, Shen RK, Haddock MG, Hofstetter WL, Maru DM, Ho L, Wu CC, Liu M, Lin SH. Multi-institutional analysis of recurrence and survival sfter neoadjuvant chemoradiotherapy of esophageal cancer: Impact of histology on recurrence patterns and outcomes. Ann Surg 269(4):663-670, 2019. e-Pub 2019. PMID: 29334555.
42. Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell 35(4):559-572.e7, 2019. e-Pub 2019. PMID: 30905761.
43. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. e-Pub 2019. PMID: 30720506.
44. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188, 2019. e-Pub 2019. PMID: 30479380.
45. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a New CDK9/p-TEFB inhibitor with and without 5-Fluorouracil in Esophageal Adenocarcinoma. Ther Adv Med Oncol 11:1-17, 2019. e-Pub 2019. PMID: 31384313.
46. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. PMID: 30420754.
47. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg 268(2):289-295, 2018. e-Pub 2018. PMID: 28628563.
48. Nelson DB, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D, Sepesi B, Antonoff MB, Mehran RJ, Rice DC, Vaporciyan AA, Davila M, Davila R, Betancourt S, Ajani J, Hofstetter WL. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg 156(1):406-413.e3, 2018. e-Pub 2018. PMID: 29605441.
49. Goense L, van Rossum PSN, Xi M, Maru DM, Carter BW, Meijer GJ, Ho L, van Hillegersberg R, Hofstetter WL, Lin SH. Preoperative nomogram to risk stratify patients for the benefit of trimodality therapy in esophageal adenocarcinoma. Ann Surg Oncol 25(6):1598-1607, 2018. e-Pub 2018. PMID: 29569125.
50. Mizuno T, Cloyd JM, Vicente D, Omichi K, Chun YS, Kopetz SE, Maru DM, Conrad C, Tzeng CD, Wei SH, Aloia TA, Vauthey JN. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol 44(5):684-692, 2018. e-Pub 2018. PMID: 29551247.
51. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's esophagus after bimodality therapy in patients with esophageal adenocarcinoma. Oncology:1-10. e-Pub 2018. PMID: 29843157.
52. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable locoregional relapses after therapy of localized esophageal cancer: Insights from a large cohort. Oncology 94(6):345-353, 2018. e-Pub 2018. PMID: 29705797.
53. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru DM, Kopetz S. Proteomic features of colorectal cancer identify tumor subtypes independent of oncogenic mutations and independently predict relapse-free survival. Ann Surgical Oncology 24(13):4051-4058, 2017. e-Pub 2017. PMID: 28936799.
54. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. e-Pub 2017. PMID: 29235564.
55. Goltsov AA, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL. HER2 confers resistance to foretinib inhibition of MET-amplified esophageal adenocarcinoma cells. Ann Thorac Surg. e-Pub 2017. PMID: 29223420.
56. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early metabolic change after induction chemotherapy predicts histologic response and prognosis in patients with esophageal cancer: Secondary analysis of a randomized trial. Target Oncology. e-Pub 2017. PMID: 29218623.
57. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 123(21):4106-4113, 2017. e-Pub 2017. PMID: 28885712.
58. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: A retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017. e-Pub 2017. PMID: 29280461.
59. Loree JM, Pereira AA, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani SM, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris J, Luthra R, Meric-Bernstam F, Overman MJ, Maru DM, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res. e-Pub 2017. PMID: 29180604.
60. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget 8(45):79356-79365, 2017. e-Pub 2017. PMID: 29108314.
61. Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. e-Pub 2017. PMID: 29084828.
62. Bhutani MS, Arora A, Kundu U, Maru DM. A rare case of pancreatic metastasis of angiosarcoma: Diagnosed by endoscopic ultrasound-guided fine-needle aspiration and biopsy. Endosc Ultrasound 6(5):340-342, 2017. e-Pub 2017. PMID: 29063874.
63. Leung ML, Davis A, Gao R, Casasent A, Wang Y, Sei E, Vilar E, Maru DM, Kopetz S, Navin NE. Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Res 27(8):1287-1299, 2017. e-Pub 2017. PMID: 28546418.
64. Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S. Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget 8(34):57882-57888, 2017. e-Pub 2017. PMID: 28915719.
65. Mizrak Kaya D, Dong X, Nogueras-González GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol 34(8):135, 2017. e-Pub 2017. PMID: 28685276.
66. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer 117(5):648-655, 2017. e-Pub 2017. PMID: 28728163.
67. Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 124(2):318-324, 2017. e-Pub 2017. PMID: 28687396.
68. Shi A, Liao Z, Allen PK, Ho L, Murphy MB, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Adv Radiat Oncol 2(3):316-324, 2017. e-Pub 2017. PMID: 29114598.
69. Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, Delclos ME, Kaur H, Maru DM, Skibber JM, Rodriguez-Bigas MA, You YN, Krishnan S, Chang GJ. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol 2(3):455-464, 2017. e-Pub 2017. PMID: 29114614.
70. Ye X, Wang R, Bhattacharya R, Boulbes DR, Fan F, Xia L, Adoni H, Ajami NJ, Wong MC, Smith DP, Petrosino JF, Venable S, Qiao W, Baladandayuthapani V, Maru DM, Ellis LM. Fusobacterium nucleatum subspecies animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors. Cancer Prev Res (Phila) 10(7):398-409, 2017. e-Pub 2017. PMID: 28483840.
71. Betancourt Cuellar SL, Sabloff B, Carter BW, Benveniste MF, Correa AM, Maru DM, Ajani JA, Erasmus JJ, Hofstetter WL. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved?. Eur J Radiol 88:56-60, 2017. e-Pub 2017. PMID: 28189209.
72. Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru DM, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery 161(2):332-340, 2017. e-Pub 2017. PMID: 27592215.
73. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani AJ, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru DM. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget 8(17):28696-28710, 2017. e-Pub 2017.
74. Denbo JW, Yamashita S, Passot G, Egger M, Chun YS, Kopetz SE, Maru DM, Brudvik KW, Wei SH, Conrad C, Vauthey JN, Aloia TA. RAS mutation Is associated with decreased survival in patients undergoing repeat hepatectomy for colorectal liver metastases. J Gastrointest Surg 21(1):68-77, 2017. e-Pub 2017. PMID: 27334313.
75. Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. Metastasis regulation by PPARD expression in cancer cells. JCI Insight 2(1):e91419, 2017. e-Pub 2017. PMID: 28097239.
76. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
77. Yamashita S, Brudvik KW, Kopetz SE, Maru DM, Clarke CN, Passot G, Conrad C, Chun YS, Aloia TA, Vauthey JN. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg. e-Pub 2016. PMID: 28002060.
78. Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G, Conrad C, Maru DM, Aloia TA, Vauthey JN. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 23(8):2635-43, 2016. e-Pub 2016. PMID: 27016292.
79. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru DM, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.
80. Shin US, Nancy You Y, Nguyen AT, Bednarski BK, Messick C, Maru DM, Dean EM, Nguyen ST, Hu CY, Chang GJ. Oncologic outcomes of extended robotic resection for rectal cancer. Ann Surg Oncol 23(7):2249-57, 2016. e-Pub 2016. PMID: 26856720.
81. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru DM, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
82. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw 14(2):173-9, 2016. e-Pub 2016. PMID: 26850487.
83. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic gastroesophageal adenocarcinoma patients treated with systemic therapy followed by consolidative local therapy: A nomogram associated with long-term survivors. Oncology 91(1):55-60, 2016. e-Pub 2016. PMID: 27120436.
84. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru DM, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33(34):4032-8, 2015. e-Pub 2015. PMID: 26460303.
85. Dhupar R, Rice RD, Correa AM, Weston BR, Bhutani MS, Maru DM, Betancourt SL, Rice DC, Swisher SG, Hofstetter WL. Endoscopic ultrasound estimates for tumor depth at the gastroesophageal junction are inaccurate: Implications for the liberal use of endoscopic resection. Ann Thorac Surg 100(5):1812-6, 2015. e-Pub 2015. PMID: 26233274.
86. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru DM, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat Med. e-Pub 2015. PMID: 26457759.
87. Boys JA, Worrell SG, Chandrasoma P, Vallone JG, Maru DM, Zhang L, Blackmon SH, Dickinson KJ, Dunst CM, Hofstetter WL, Lada MJ, Louie BE, Molena D, Watson TJ, DeMeester SR. Can the risk of lymph node metastases be gauged in endoscopically resected submucosal esophageal adenocarcinomas? A multi-center study. J Gastrointest Surg. e-Pub 2015. PMID: 26408330.
88. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. e-Pub 2015. PMID: 26321501.
89. Shindoh J, de Aretxabala X, Aloia TA, Roa JC, Roa I, Zimmitti G, Javle M, Conrad C, Maru DM, Aoki T, Vigano L, Ribero D, Kokudo N, Capussotti L, Vauthey JN. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: An international multicenter study. Ann Surg 261(4):733-9, 2015. e-Pub 2015. PMID: 24854451.
90. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520(7549):697-701, 2015. e-Pub 2015. PMID: 25901683.
91. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
92. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, Cooper AB, Kaur H, Aloia TA, Maru DM, Vauthey JN. RAS Mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 22(3):834-42, 2015. e-Pub 2015. PMID: 25227306.
93. Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 6(1):45-52, 2015. e-Pub 2015. PMID: 25642337.
94. Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, Lanza G, Stork-Sloots L, Maru D, Simon I, Capellà G, Salazar R. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist 20(2):127-33, 2015. e-Pub 2015. PMID: 25561511.
95. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2015. PMID: 25535726.
96. Karapetis CS, Maru D, Waring P, Tie J, Michael MZ. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. Expert Rev Mol Diagn 15(8):1033-48, 2015. e-Pub 2015. PMID: 26166616.
97. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology 88(6):332-6, 2015. e-Pub 2015. PMID: 25765098.
98. Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 2014. e-Pub 2014. PMID: 25205085.
99. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru DM, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of Non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
100. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 32(30):3400-5, 2014. e-Pub 2014. PMID: 25225435.
101. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
102. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. Ann Thorac Surg 98(3):1064-71, 2014. e-Pub 2014. PMID: 25038008.
103. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res 74(15):4170-82, 2014. e-Pub 2014. PMID: 24906622.
104. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw 12(8):1139-44, 2014. e-Pub 2014. PMID: 25099446.
105. Maru DM, Agarwal AA, Hu CY, Chang GJ. Reply to "Can" quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?. Cancer 120(8):1282, 2014. e-Pub 2014. PMID: 24474599.
106. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent Capecitabine, Bevacizumab, and Erlotinib for rectal cancer: A Phase I Trial. Int J Radiat Oncol Biol Phys 88(2):301-5, 2014. e-Pub 2014. PMID: 24315563.
107. Bailey AM, Zhan L, Maru DM, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL. FXR Silencing in human colon cancer by DNA Methylation and KRAS Signaling. Am J Physiol Gastrointest Liver Physiol 306(1):G48-58, 2014. e-Pub 2014. PMID: 24177031.
108. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology 86(5-6):336-9, 2014. e-Pub 2014. PMID: 24925190.
109. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14:660, 2014. e-Pub 2014. PMID: 25208577.
110. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Local-regional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 31(34):4306-10, 2013. e-Pub 2013. PMID: 24145339.
111. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 2013. e-Pub 2013. PMID: 24089344.
112. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. Ras mutational status predicts patterns of recurrence and survival in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258(4):619-27, 2013. e-Pub 2013. PMID: 24018645.
113. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Molecular Oncology, 2013. e-Pub 2013.
114. Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL, Cancer Group UOTMAE. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg 258(3):500-7, 2013. e-Pub 2013. PMID: 24022442.
115. Brouquet A, Zimmitti G, Kopetz S, Stift J, Julié C, Lemaistre AI, Agarwal A, Patel V, Benoist S, Nordlinger B, Gandini A, Rivoire M, Stremitzer S, Gruenberger T, Vauthey JN, Maru DM. Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 119(13):1-11, 2013. e-Pub 2013. PMID: 23868456.
116. Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, Ajani JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. e-Pub 2013. PMID: 23994746.
117. J A Ajani J, L Xiao L, J A Roth J, W L Hofstetter W, GWalsh, RKomaki, Z Liao Z, D C Rice D, A A Vaporciyan A, Maru DM, J H Lee J, M S Bhutani M, A Eid A, J C Yao1 J, A P Phan A, A Halpin A, ASuzuki1, T Taketa T, P F Thall P, G Swisher AS. A Phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol, 2013. e-Pub 2013.
118. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 257(6):1079-88, 2013. e-Pub 2013. PMID: 23426338.
119. Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet?. Clin Cancer Res 19(11):2824-7, 2013. e-Pub 2013. PMID: 23549876.
120. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 24(5):1262-6, 2013. e-Pub 2013. PMID: 23247658.
121. Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L. Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res 73(7):2159-69, 2013. e-Pub 2013. PMID: 23536563.
122. Chen WC, Maru DM, Abraham SC, Tan D, Raju GS. Endoscopic clip tamponade of bleeding: a novel adjunct technique for endoscopic mucosal resection. Endoscopy. e-Pub 2013. PMID: 23526499.
123. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, Maru DM, Hawke DH, Rak J, Mani SA, Zweidler-McKay P, Ellis LM. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of jagged-1. Cancer Cell 23(2):171-85, 2013. e-Pub 2013. PMID: 23375636.
124. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology 85(4):204-7, 2013. e-Pub 2013. PMID: 24051869.
125. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer. Eur J Cancer 48(18):3396-404, 2013. e-Pub 2013. PMID: 22853875.
126. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology 85(2):95-99, 2013. e-Pub 2013. PMID: 23860252.
127. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30(36):4566-72, 2012. e-Pub 2012. PMID: 23150701.
128. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru DM, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after failed definitive chemo radiation for esophageal adenocarcinoma. Ann Thorac Surg 94(4):1126-32, 2012. e-Pub 2012. PMID: 22921233.
129. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki Jr R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Annals of Oncology 23(10):2638-42, 2012. e-Pub 2012. PMID: 22831985.
130. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg 256(4):642-50, 2012. e-Pub 2012. PMID: 22968062.
131. Thekkek N, Muldoon T, Polydorides AD, Maru DM, Harpaz N, Harris MT, Hofstettor W, Hiotis SP, Kim SA, Ky AJ, Anandasabapathy S, Richards-Kortum R. Vital-dye enhanced fluorescence imaging of GI mucosa: metaplasia, neoplasia, inflammation. Gastrointest Endosc 75(4):877-87, 2012. e-Pub 2012. PMID: 22301343.
132. Harvin JA, Lahat G, Correa AM, Lee J, Maru DM, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg 143(2):412-20, 2012. e-Pub 2012.
133. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome?. Ann Thorac Surg 93(1):207-12; discussion 212-3, 2012. e-Pub 2012. PMID: 21962263.
134. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology 83(5):300-4, 2012. e-Pub 2012. PMID: 22964903.
135. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 82(2):108-13, 2012. e-Pub 2012. PMID: 22328056.
136. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz S, Loyer EM. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with Bevacizumab. AJR Am J Roentgenol 197(6):W1060-6, 2011. e-Pub 2011. PMID: 22109320.
137. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-33, 2011. e-Pub 2011. PMID: 21456015.
138. Thekkek N, Maru DM, Polydorides AD, Bhutani MS, Anandasabapathy S, Richards-Kortum R. Pre-clinical evaluation of fluorescent deoxyglucose as a topical contrast agent for the detection of Barrett's-associated neoplasia during confocal imaging. Technol Cancer Res Treat 10(5):431-41, 2011. e-Pub 2011.
139. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20):4623-32, 2011. e-Pub 2011. PMID: 21456008.
140. Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 117(19):4484-92, 2011. e-Pub 2011. PMID: 21446046.
141. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-22, 2011. e-Pub 2011. PMID: 22150920.
142. Ferrarotto R, Pathak P, Maru DM, Agarwal A, Overman M, Hoff PM, Kopetz S. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 2011. e-Pub 2011.
143. Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das P. Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer 117(16):3713-22, 2011. e-Pub 2011. PMID: 21328329.
144. Mendelson J, Song S, Li Y, Maru DM, Mishra B, Davila M, Hofstetter WL, Mishra L. Dysfunctional TGF-beta signaling with constitutively Notch signaling in Barrett`s esophageal adenocarcinoma. Cancer 117(16):3691-702, 2011. e-Pub 2011. PMID: 21305538.
145. Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL, Eng C. Association of CHFR Promoter Methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res 17(13):4531-40, 2011. e-Pub 2011. PMID: 21551253.
146. Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol 35(7):1045-53, 2011. e-Pub 2011. PMID: 21602659.
147. Kountourakis P, Correa A M, Hofstetter WL, Lee J H, Bhutani M, Rice D, Komaki R, Maru D, Ross W, Vaporcian A, Swisher S G, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: UT M.D. Anderson Cancer Center Experience. Cancer 117(5):925-30, 2011. e-Pub 2011. PMID: 20960497.
148. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Maru D, Watson TJ, Foregut Group SSMDAECGUORSOMAD. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer 117(1):63-9, 2011. e-Pub 2011. PMID: 20803613.
149. Goodarzi M, Rashid A, Maru DM. Invasive ductal adenocarcinoma arising from pancreatic heterotopia in rectum: A case report and review of literature. Human Pathology 41(12):1809-13, 2010. e-Pub 2010. PMID: 20869744.
150. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastasis. Ann Surg Oncol 17(11):2870-6, 2010. e-Pub 2010. PMID: 20567921.
151. Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru DM, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 5(11):e15074, 2010. e-Pub 2010. PMID: 21152079.
152. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN, Loyer EM. Tumor thickness at the tumor-normal interface: A novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34(9):1287-1294, 2010. e-Pub 2010. PMID: 20697255.
153. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: An orphan status. Ann Thorac Surg 90(3):884-891, 2010. e-Pub 2010. PMID: 20732513.
154. Diagaradjane P, Deorukhkar A, Gelovani JG, Maru DM, Krishnan S. Gadolinium Chloride augments tumor-specific imaging of targeted quantum dots in vivo. ACS Nano 4(7):4131-41, 2010. e-Pub 2010. PMID: 20586481.
155. Harikumar A, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 9(5):1136-46. e-Pub 2010. PMID: 20442301.
156. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28(15):2549-55, 2010. e-Pub 2010. PMID: 20406923.
157. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Tri-Modality Therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer 116(7):1656-63, 2010. e-Pub 2010. PMID: 20143431.
158. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru D, Ellis LM, Rodriguez-Bigas MA. Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76(3):824-30, 2010. e-Pub 2010. PMID: 1964823.
159. Muldoon TJ, Thekkek N, Roblyer D, Maru D, Harpaz N, Potack J, Anandasabapathy S, Richard-Kortum R. Evaluation of quantitative image analysis criteria for the high-resolution microendoscopic detection of neoplasia in Barrett's esophagus. J Biomed Opt 15(2):026027. e-Pub 2010. PMID: 20459272.
160. Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol 22(12):1612-21, 2009. e-Pub 2009. PMID: 19734842.
161. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302(21):2338-44, 2009. e-Pub 2009. PMID: 19952320.
162. Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115(22):5184-92, 2009. e-Pub 2009. PMID: 19685531.
163. Bolton WD, Hofstetter WL, Correa AM, Ajani JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg 138(4):831-6, 2009. e-Pub 2009. PMID: 19660349.
164. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 2009. e-Pub 2009. PMID: 19822514.
165. Swisher SG, Hofstetter WL, Komaki R, Correa AM, Erasmus J, Lee J H, Liao Z, Maru DM, Mehran R, Patel S, Rice D, Roth JA, Vaporcian AA, Walsh GL, Ajani JA. Improved long-term outcome with chemotherapy strategies in esophageal cancer. Annals of Thoracic Surgery 90(3):892-899. e-Pub 2009. PMID: 20732514.
166. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol 174(5):1940-8, 2009. e-Pub 2009. PMID: 19342367.
167. Maru D, Luthra R, White-Cross J, Anadasabapathy S, Guha S, Krishnan S, Komaki R, Swisher S, Ajani J, Hofstetter W, Rashid A. Frequent loss of Heterozygosity of Chromosome 1q in esophageal adenocarcinoma; Loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 115(7):1576-85, 2009. e-Pub 2009. PMID: 19156915.
168. Yendamuri S, Swisher SG, Correa AM, Hofstetter W, Ajani JA, Francis A, Maru D, Mehran RJ, Rice D, Roth JA, Walsh GL, Vaporciyan AA. Esophageal tumor length is independently associated with long-term survival. Cancer 115(3):508-16, 2009. e-Pub 2009. PMID: 19117343.
169. Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 115(3):624-30, 2009. e-Pub 2009. PMID: 19130466.
170. Anandasabapathy S, Maru D, Klumpp S, Uthamanthil R, Borne A, Bhutani MS. Novel endoscopic application of a new flexible-fiber CO2 laser for esophageal mucosal ablation in a porcine model. Endoscopy 41(2):138-42, 2009. e-Pub 2009. PMID: 19214893.
171. Leung KK, Maru D, Abraham S, Hofstetter WL, Mehran R, Anandasabapathy S. Optical EMR: Confocal endomicroscopy-targeted EMR of focal high grade dysplasia in Barrett’s esophagus. Gastrointest Endosc 69(1):170-2, 2009. e-Pub 2009. PMID: 18582880.
172. Chun Y, Laurent AL, Maru DM, Vauthey J. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncology(10):278-286, 2009. e-Pub 2009.
173. Maru DM. Barrett esophagus: Review of diagnostic challenges and new developments. Annals of Diagnostic Pathology(13):212-221, 2009. e-Pub 2009.
174. Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 22(2):127-32, 2009. e-Pub 2009. PMID: 19021681.
175. Cen P, Correa A, Lee J, Maru D, Anandasabapathy S, Liao Z, Hofstetter W, Swisher S, Komaki R, Ross W, Vaporciyan A, Ajani J. Adenocarcinoma of the lower esophagus with Barrett's Esophagus or without Barrett's Esophagus: Differences in patients survival after preoperative chemoradiation. Dis Esophagus 22(1):32-41, 2009. e-Pub 2009. PMID: 19021684.
176. 3rd BD, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of Hepatic Colorectal Metastasis. Journal of Clinical Oncology 26(33):5344-51, 2008. e-Pub 2008. PMID: 18936472.
177. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 27(52):6667-78, 2008. e-Pub 2008. PMID: 18663355.
178. Muldoon TJ, Anandasabapathy S, Maru D, Richards-Kortum R. High-resolution imaging in Barrett's Esophagus: a novel, low-cost endoscopic microscope. Gastrointest Endosc 68(4):737-44, 2008. e-Pub 2008. PMID: 18926182.
179. Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, Ajani JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys 71(1):167-72, 2008. e-Pub 2008. PMID: 18406886.
180. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, Ajani JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus 21(7):575-81, 2008. e-Pub 2008. PMID: 18459989.
181. Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, Ajani JA. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer 112(5):1020-1028, 2008. e-Pub 2008. PMID: 18205187.
182. Anandasabapathy S, Maru D, Klump S, Bhutani M. Evaluation of a new flexible fiber CO2 laser for gastrointestinal cutting: Notes and mucosectomy in a Porcine Mode. Endoscopy 40(Suppl 2):E200-1, 2008. e-Pub 2008. PMID: 18709617.
183. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 113(6):1302-8, 2008. e-Pub 2008. PMID: 18623381.
184. Maru D, Khurana H, Rashid A, Correa A, Anandasabapathy S, Krishnan S, Komaki R, Ajani J, Swisher S, Hofstetter W. Retrospective study of clinicopathologic features and prognosis of high-grade Neuroendocrine Carcinoma of the esophagus. American Journal of Surgical Pathology 32(9):1404-11, 2008. e-Pub 2008. PMID: 18670347.
185. Gujral S, Jain M, Maru D, Nair C. De Novo Diffuse large B Cell lymphoma with co-expression of CD5 and CD23. Am J Hematology 82(7):684-5, 2007. e-Pub 2007. PMID: 17315215.
186. Hingmire S, Narayanan P, Biswas G, Maru D, Sastry PS, Parikh P. Isolated cutaneous relapse of acute Myeloid Leukemia. J Assoc Physicians India 55:131, 2007. e-Pub 2007. PMID: 17571743.
187. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC Esophageal Cancer Staging System. Ann Thorac Surg 84(2):365-373, 2007. e-Pub 2007.
188. Prabhash K, Biswas G, Nair R, Pandey D, Maru D, Mahajan A, Parikh PM. Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma. Indian J Gastroenterol 25(5):261-2, 2006. e-Pub 2006. PMID: 17090851.
189. Laskar S, Muckaden MA, Nair R, Gupta S, Maru D, Dinshaw K. Primary non-Hodgkin's Lymphoma of the Nasopharynx: Prognostic factors and outcome of 113 Indian patients. Leukemia and Lymphoma 47(10):2132-2139, 2006. e-Pub 2006.
190. Trofe J, Roy-Chaudhary P, Gordon J, Wadih G, Maru D, Cardi M, Succop P, Alloway R, Khalili K, Woodle E. Outcomes of patients with rejection post-polyomavirus nephropathy. Transplant Proceedings 37(2):942-944, 2005. e-Pub 2005.
191. Maru DM, Middleton LP, Wang S, Valero V, Sahin A. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and Younger. Cancer 103(5):900-905, 2005. e-Pub 2005.
192. Maru D, Moran C. Carcinoid tumor of lung. American Society of Clinical Pathology, Check Sample, 2004. e-Pub 2004.
193. Maru DM, Wu TT, Canada A, Houlihan P, Cleary K, Hamilton S, Rashid A. Frequent loss of chromosome 18q and DPC4 mutations in mucinous and non-mucinous appendiceal adenocarcinomas. Oncogene 23(3):859-864, 2004. e-Pub 2004.
194. Neipp M, Exner BG, Maru DM, Haber M, Gammie JS, Pham SM, Ildstad ST. T-cell depletion of allogeneic bone marrow using anti-alphabetaTCR monoclonal antibodies: Prevention of graft versus host disease without affecting the engraftment potential in rats. Experimental Hematology 27(5):860-867, 1999. e-Pub 1999.

Invited Articles

1. Maru DM. The immune response in cancer: From immunology to pathology to immunotherapy, 2017. e-Pub 2017.
2. Maru DM. Barretts esophagus: Review of diagnostic challenges and new developments. Annals of Diagnostic Pathology 13:212-21, 2009. e-Pub 2009.
3. Chun Y, Laurent AL, Maru DM, Vauthey J. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncology 10:278-86, 2009. e-Pub 2009.
4. Maru DM. Sporadic microsatellite instability-high colon carcinoma with hMLH1 Promoter Methylation. American Society of Clinical Pathology, Check Sample, 2008. e-Pub 2008.

Review Articles

1. Chan SCC, Choa G, Kelly J, Maru D, Rashid MA. Implementation of virtual OSCE in health professions education: A systematic review. Med Educ 57(9):833-843, 2023. e-Pub 2023. PMID: 37080907.
2. Stigwood A, Ashmore AA, Maru D, Soni L. Review of literature for ethnic minority-led GP practices: impact and experience of CQC regulation. BMJ Lead 7(1):12-15, 2023. e-Pub 2023. PMID: 37013878.
3. Maru D, Kumar A. Phytochemicals in the Synthetic Era: A Potential Oncosuppressor against Cancer Stem Cells. Anticancer Agents Med Chem 23(11):1242-1252, 2023. e-Pub 2023. PMID: 36843373.
4. Waring P, Tie J, Maru DM, Karapetis CS. RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer. Clin Colorectal Cancer 15(2):95-103, 2016. e-Pub 2016. PMID: 26952655.

Professional Educational Materials

1. Maru D. Platelet Function Tests, Lab Lines. University of Cincinnati Medical Center, 2000.

Other Articles

1. Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 597(7875):E6, 2021. PMID: 34433970.

Abstracts

1. Elzamly S, Al-Attar M, Taggart M, Foo WC, Maru D, Chatterjee D. SMARCA4-Deficient Carcinoma of the Esophagus: Diagnostic Challenges with Synaptophysin Expression and Therapeutic Implications, 2024. e-Pub 2024.
2. Jadhav A, Khanduri I, Zhang S, Mejia A, Soto LS, Tong Z, Wistuba I, Parra E, Kopetz S, Maru D. Co-expression in the Tumor Associated Macrophages is Associated with Lymph Node Metastasis, Lymphovascular invasion and MSI-H Status in Primary Colorectal Carcinoma, 2024. e-Pub 2024.
3. Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Overman MJ, Kopetz S. Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients. Gastrointestinal Cancers Symposium 36(4):653, 2018. e-Pub 2018.
4. Mehrvarz Sarshekeh A, Loree J, Lima Pereira AA, Raghav KPS, Lam M, Advani SM, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies. Gastrointestinal Cancers Symposium 36(4):640, 2018. e-Pub 2018.
5. Nusrat M, Manyam GC, Loree JM, Lam M, Overman MJ, Maru DM, Routbort M, Morris J, Kopetz S. Molecular characterization of TP53 mutations and copy number change in colorectal cancers. American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
6. Reilley M, Basu S, Katkhuda R, Patterson N, Chen T, Blando JM, Menter D, Maru DM, Allison JP, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
7. JM Loree JM, Korphaisarn KK, Lam M, Morris VK, Raghav KP, Overman MJ, Eng C, Dasar A, Kee BK, Fogelman D, Wolff RA, Shaw K, Broaddus R, Routbort MJ, Luthra R, Maru DM, Menter DG, Meric-Bernstam F, Kopetz S. APCWT/RASWT/BRAFWT tumors represent an under recognized poor prognostic group of right sided colorectal cancer. American Association of Cancer Research Annual Meeting 2017, 2017. e-Pub 2017.
8. Nelson DB, Correa A, Dhupar R, Goltsov A, Maru DM, Sepesi B, Antonoff M, Mehran RJ, Rice DC, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Davila R, Betancourt S, Skinner H, Blum M, Hofstetter W. Endoscopic mucosal resection for submucosal esophageal cancer. AATS, 2017. e-Pub 2017.
9. Loree JM, Lam M, Morris J, Overman MJ, Raghav KPS, Eng C, Dasari A, Kee BK, Fogelman DR, Wolff RA, Jiang Z, Davis JS, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Menter D, Meric-Bernstam F, Kopetz S. RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. Journal of Clinical Oncology 35(4):586, 2017. e-Pub 2017.
10. Goltsov A, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL. HER2 amplification confers resistance to targeted therapy in esophageal adenocarcinoma cells with concomitant amplification of MET. STS, 2017. e-Pub 2017.
11. Korphaisarn K, Chou CK, Xia WY, Clarke CN, Katkhuda R, Davis JS, Raghav KP, Liao HW, Wu JY, Menter DG, Maru DM, Hung MC, Kopetz S. Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. Am J Cancer Res 7(12):2587-2599, 2017. e-Pub 2017. PMID: 29312811.
12. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology 93(4):243-248, 2017. e-Pub 2017. PMID: 28683449.
13. Reilley M, Blando JM, Katkhuda R, Menter D, Sharma P, Allison JP, Kopetz S, Maru DM, Overman JM. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. Journal of Clinical Oncology 34, 2016. e-Pub 2016.
14. Shin US, You YN, Price BA, Rodriguez-Bigas MA, Skibber JM, Maru DM, Taggart MW, Kopetz SB, Eng C, Minsky BD, Das P, Krishnan S, Chang GJ. Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)?. Journal of Clinical Oncology 34, 2016. e-Pub 2016.
15. Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer 114(12):1352-61, 2016. e-Pub 2016. PMID: 27272216.
16. Raghav K, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shanmugam K, Maru DM, Fakih D, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting, 2016. e-Pub 2016.
17. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Shureiqui I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S, Dasari A. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in Metastatic Colorectal Cancer (mCRC) patients (pts). Journal of Clinical Oncology 34, 2016. e-Pub 2016.
18. Raghav KPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shanmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. Journal of Clinical Oncology 34, 2016. e-Pub 2016.
19. Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Manuel S, Shureiqui I, Wolff RA, Patel K, Luthra R, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. Journal of Clinical Oncology 34(45):565, 2016. e-Pub 2016.
20. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Rodriguez J, Ajani J, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru DM. Cyclin-dependent kinase 9: A potential therapeutic target for esophageal adenocarcinoma. American Association of Cancer Research 107th Annual Meeting), 2016. e-Pub 2016.
21. Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Manuel S, Shureiqui I, Wolff RA, Patel K, Luthra R, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S. Demographic, tumor charateristics and outcomes associated with SMAD4 mutation in colorectal cancer. GI American Society of Clinical Oncology Annual Meeting, 2016. e-Pub 2016.
22. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Shureiqui I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S, Dasari A. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic Colorectal Cancer (mCRC) patients (pts). American Society of Clinical Oncology Annual Meeting, 2016. e-Pub 2016.
23. Elimova E, Kim SM, Wang X, Shimodaira Y, Sohn BH, Skinner HD, Lee JH, Weston BR, Bhutani MS, Minsky B, Rice DC, Hwang JE, Swisher SG, Hofstetter WL, Blum MA, Maru DM, Ajani JA, Lee JS. Correlation of pretreatment p63-positive subtype of gastroesophageal adenocarcinoma (GEAC) with pathologic complete response (pathCR) in patients receiving preoperative chemoradiation. Gastrointestinal Cancers Symposium, 2016. e-Pub 2016.
24. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Shiozaki H, Minsky B, Das P, Hofstetter W, Swisher S, Skinner H, Maru DM, Matamoros A, Blum M, Lee J, Weston B, Bhutani M, Mansfield P, Badgwell B, Ajani J. Outcomes in older patients with localized gastric adenocarcinoma treated preoperatively. American Society of Clinical Oncology Annual Meeting, 2016. e-Pub 2016.
25. Lee MS, Advani SM, Morris J, Jiang Z, Manyam GC, Menter D, McIntosh Broom B, Eng C, Overman MJ, Maru DM, Hamilton SR, Kopetz S. Association of primary (1°) site and molecular features with Progression-Free Survival (PFS) and Overall Survival (OS) of Metastatic Colorectal Cancer (mCRC) after Anti-Epidermal Growth Factor Receptor (αEGFR) therapy. American Society of Clinical Oncology Annual Meeting, 2016. e-Pub 2016.
26. Lee MS, Advani SM, Morris J, Jiang Z, Manyam GC, Menter D, McIntosh Broom B, Eng C, Overman MJ, Maru DM, Hamilton SR, Kopetz S. Association of primary (1°) site and molecular features with Progression-Free Survival (PFS) and Overall Survival (OS) of Metastatic Colorectal Cancer (mCRC) after Anti-Epidermal Growth Factor Receptor (αEGFR) therapy. American Society of Clinical Oncology Annual Meeting, 2016. e-Pub 2016.
27. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot B, Morris JS, Simon I, Gerster S, Fessler E, de Sousa e Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru DM, Manyam G, Broom B, Boige V, Laderas T, Salazar R, Gray JW, Tabernero J, Bernards R, Friend S, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation. American Association of Cancer Research 106th Annual Meeting, 2015. e-Pub 2015.
28. Advani SM, Lee MS, Overman MJ, Fogelman D, Kee BK, Manuel SD, Davis J, Morris VK, Clarke CN, Daniel CR, Menter DG, Hamilton SR, Maru DM, Kopetz S. Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients. American Association of Cancer Research 106th Annual Meeting, 2015. e-Pub 2015.
29. Boys JA, Worrell SG, Chandrasoma P, Dunst CM, Hofstetter WL, Louie BE, Maru DM, Vallone JG, Watson TJ, DeMeester SR. Can the risk of lymph node metastases be gauged in endoscopically resected submucosal esophageal adenocarcinomas? A multi-center study. Digestive Disease Week, 2015. e-Pub 2015.
30. Clarke C, Lee MS, Manyam GC, Jiang ZQ, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Raghav KPS, Eng C, Chang GJ, Overman MJ, Maru DM, Kopetz S. Proteomic features of colorectal cancer independently predict relapse-free survival. Journal of Clinical Oncology 33(3):616, 2015. e-Pub 2015.
31. Raghav KPS, Tang C, Morelli MP, Amin HM, Chen K, Manyam GC, Broom BM, Talasaz A, Overman MJ, Shaw KR, Meric-Bernstam F, Maru DM, Eng C, Hong DS, Kopetz S. Multiple independent methods fail to confirm MET amplification rate reported in literature for Metastatic Colorectal Cancer (mCRC). Journal of Clinical Oncology 33(3):572, 2015. e-Pub 2015.
32. Morris VK, James B, Tian F, Jiang ZQ, Overman MJ, Maru DM, Menter D, Powis G, Kopetz S. Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated Metastatic Colorectal Cancer (mCRC). Journal of Clinical Oncology 33(3):629, 2015. e-Pub 2015.
33. Lee MS, Clarke C, Jiang ZQ, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. Journal of Clinical Oncology 33(3):580, 2015. e-Pub 2015.
34. Lee MS, Clarke C, Jiang Z, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. Journal of Clinical Oncology 33(3), 2015. e-Pub 2015.
35. Agarwal A, Tan D, Abraham S, Taggart M, Wang H, Estrella J, Zhang M, Rashid A, Maru DM. Retrospective study of clinicopathologic features and patient outcome of primary adenosquamous carcinoma of the esophagus. United States and Canadian Academy of Pathology, Boston, MA, 2015. e-Pub 2015.
36. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Planjery V, Nkis C, Skinner HD, Lee JH, Weston B, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Failures (LRFs) after therapy of Localized Esophageal Carcinoma (LEC): Surveillance strategies and their benefits. Gastrointestinal Cancers Symposium, 2015. e-Pub 2015.
37. Dhupar R, Correa A, Rice R, Bhutani M, Weston B, DaSilva A, Maru DM, Betancourt S, Rice DC, Swisher SG. Endoscopic ultrasound estimates for tumor depth at the gastroesophageal junction are less accurate for early mid-stage patients: Implications for the liberal use of endoscopic resection. 51st Annual Meeting of The Society of Thoracic Surgeons, 2015. e-Pub 2015.
38. Lee MS, Overman MJ, Maru DM, Jiang Z, Manuel S, Eng C, Kee BK, Fogelman DR, Garrett CR, Advani SM, Sanchez EV, Shureiqi I, Wolff RA, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. Journal of Clinical Oncology 32(5), 2014. e-Pub 2014.
39. Pereira AAL, De Mendonga Rego FJ, Morris VK, Overman MJ, Eng C, Garrett CR, Ferrarotto R, Lee MS, Jiang Z, Hoff PM, Vauthey J, Vilar Sanchez E, Maru DM, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Journal of Clinical Oncology 32(3):494, 2014. e-Pub 2014.
40. Francis AM, Correa AM, Betancourt-Cuellar SL, Kim JY, Sepesi B, Ajani JA, Komaki R, Erasmus J, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Hofstetter WL, Swisher SG. Esophageal tumor thickness on computed tomography as a predictor of residual tumor in esophageal adenocarcinoma following preoperative chemoradiation. Academic Surgical Congress, 2014. e-Pub 2014.
41. Shiozaki H, Sudo K, Wadhwa R, Elimova E, Slack R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Hofstetter WL, Ajani JA. Effect of the distribution of lymph node metastases on outcomes for trimodality-eligible patients with esophageal and Esophagogastric Junction Adenocarcinoma (EAC). American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
42. Agarwal A, Manyam G, Jiang ZQ, Neishaboori N, Agarwal S, Overman M, Broom B, Roepman P, Simon I, Kopetz S, Maru DM. Role of intraepithelial lymphocyte density in the transcriptome of microsatellite stable primary colon cancer. United States and Canadian Academy of Pathology, San Diego, CA, 2014. e-Pub 2014.
43. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. Journal of Clinical Oncology 32, 2014. e-Pub 2014.
44. Morris VK, Overman MJ, Maru DM, Kopetz S. Progression-free survival in metastatic, BRAF-mutated colorectal cancer. Journal of Clinical Oncology 31(4):458, 2013. e-Pub 2013.
45. Lieu CH, Varella-Garcia M, Xu LG, Jiang Z, Eckhardt SG, Messersmith WA, Maru DM, Kopetz S. Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer. Journal of Clinical Oncology 31(4):402, 2013. e-Pub 2013.
46. Jiang Z, Deaton L, Neishaboori N, Vauthey JN, Overman MJ, Maru DM, Kopetz S. Molecular characteristics of complete PTEN loss in metastatic colorectal cancer. Journal of Clinical Oncology 31(4):389, 2013. e-Pub 2013.
47. Agarwal A, Brouquet A, Zimmitti G, Kopetz S, Stift J, Julie C, Lemaistre AI, Benoist S, Nordlinger B, Gandini A, Rivoire M, Stremitzer S, Gruenberger T, Vauthey JN, Maru DM. Multicenter validation study of pathologic response and tumor thickness at the tumor–normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastasis. United States and Canadian Academy of Pathology, 2013. e-Pub 2013.
48. Kopetz S, Jiang Z, Overman MJ, Rosenberg R, Salazar R, Tabernero J, Stork L, Li Y, Simon I, Chang GJ, Maru DM. Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. Journal of Clinical Oncology 31:3612, 2013. e-Pub 2013.
49. Sun H, Hatzis C, Fu C, Avritscher R, Ahrar K, Tam A, Curley S, Yao H, Vauthey JN, Valero V, Booser D, Maru DM, Hamilton S, Luthra R, Lau R, Gould RE, Pusztai J, Wallace M, Symmans WF. The proportion of contaminating host organ RNA within clinical biopsies of metastatic breast cancer is minimal. United States and Canadian Academy of Pathology, 2013. e-Pub 2013.
50. Agarwal A, Chang G, Hu YC, Taggart M, Rashid A, Kopetz S, Maru DM. Residual tumor burden in rectal cancer: A new method of assessing pathologic response to neoadjuvant therapy. United States and Canadian Academy of Pathology, 2013. e-Pub 2013.
51. Morris VK, Overman MJ, Eng C, Vilar Sanchez E, Morelli MP, Jiang Z, Luthra R, Maru DM, Meric-Bernstam F, Kopetz S. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. Journal of Clinical Oncology 31, 2013. e-Pub 2013.
52. Morris VK, Overman MJ, Eng C, Sanchez EV, Morelli M, Jiang Z, Luthra R, Maru DM, Meric-Bernstam F, Cancer Center KSTUOTMA, Houston, Sciences Center TUOCH, Denver, CO. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. Journal of Clinical Oncology, American Society of Clinical OncologyAnnual Meeting((abstr 3612)), 2013. e-Pub 2013.
53. Singh A, Hofstetter WL, Bhattacharya A, Ladha HS, Qiao W, Ross WA, Bhutani MS, Krishna SG, Ajani JA, Maru DM, Lee JH. Accuracy of endoscopic ultrasound in differentiation of mucosal and submucosal esophageal cancer at a tertiary cancer care center. Digestive Disease Week, 2013. e-Pub 2013.
54. Kopetz S, Z-Q J, Overman MJ, Dreezen C, Tian S, Li Y, Simon I, Change GJ, Maru DM. Genomic classifiers (ColorPrint/MSI-Print) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. GI American Society of Clinical Oncology Annual Meeting, 2013. e-Pub 2013.
55. Kopetz S, Jiang ZQ, Overman MJ, Rosenberg R, Salazar R, Tabernero J, Stork L, Li Y, Simon I, Chang GJ, Cancer Center MDTUOTMA, Houston, of Surgery TD, Baden K, Baden, Medical Oncology SDO, Oncologia IC, IDIBELL, Llobregat HD, Oncology Department SM, University Hospital VD, Barcelona, Inc SA, Amsterdam, Agendia N, Inc, Irvine, CA; Agendia NV, Amsterdam, Netherlands. Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting((abstr 3632)), 2013. e-Pub 2013.
56. Sucharita Cheedella NK, Suzuki A, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Maru DM, Vaporciyan AA, Taketa T, Blum MA, Welsh J, Lin SH, Lee JH, Bhutani MS, Weston B, Walsh GL, Swisher S, Ajani JA. Association of Clinical Complete Response (cCR) after preoperative chemoradiation and Pathological Complete Response (pathCR) in patients with Gastroesophageal Cancer (GEC) and indispensability of Trimodality Therapy (TMT). Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting 30(15), 2012. e-Pub 2012.
57. Suzuki A, Xiao L, Taketa T, Blum MA, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Rice DC, Mehran RJ, Maru DM, Erasmus JJ, Hofstetter WL, Swisher S, Ajani JA. Customization of treatment for patients with Esophageal Adenocarcinoma (EAC) who achieve Clinical Complete Response (cCR) after chemoradiation using Initial Standardized Uptake Value (iSUV) of 18f-fluorodeoxyglucose PET. Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting 30(15 Supplement (4069)), 2012. e-Pub 2012.
58. Taketa T, Correa AM, Suzuki A, Blum MA, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Swisher S, Hofstetter WL, Ajani AJ. Outcome of 58 trimodality-eligible Esophagogastric Cancer (EC) patients who achieved Clinical Complete Response (cCR) after preoperative chemoradiation but then declined surgery. Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting 30(15), 2012. e-Pub 2012.
59. Lin SH, Wang L, Myles BH, Thall PF, Hofstetter WL, Swisher S, Lee JE, Bhutani MS, Maru DM, Ajani JA, Ho L, Cox JD, Komaki R, Liao ZX. Inverse-probability weighted and propensity score-based analysis of long-term clinical outcomes comparing 3D Conformal Radiotherapy (3DCRT) with Intensity-Modulated Radiation Therapy (IMRT) in the treatment of esophageal cancer. Journal of Clincial Oncology, American Society of Clinical Oncology Annual Meeting 30(15), 2012. e-Pub 2012.
60. Morris VK, Parikh N, Overman M, Jiang ZQ, Maru DM. Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer. Journal of Clinical Oncology 30(15), 2012. e-Pub 2012.
61. Blum MA, Hayashi Y, Xiao L, Suzuki A, Sabloff B, Maru DM, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Swisher S, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer. Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting 30(15), 2012. e-Pub 2012.
62. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Maru DM, Munsell MF, Clemons MV, Kopetz S, Garrett CR, Shureiqi I, Krishnan S, Delclos ME, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. Journal of Clinical Oncology 30(4):544, 2012. e-Pub 2012.
63. Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru DM, Elvin D, Kopetz S, Gallick GE. Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer. Journal of Clinical Oncology 30:3561, 2012. e-Pub 2012.
64. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Maru DM, Munsell MF, Clemons MV, Kopetz S, Garrett CR, Shureiqi I, Krishnan S, Delclos ME, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. Journal of Clinical Oncology 30, 2012. e-Pub 2012.
65. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru DM, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. Journal of Clinical Oncology 29(4):399, 2011. e-Pub 2011.
66. Boonsirikamchi P, Maru DM, Chun Y, Kaur H, Kopetz S, Loyer E M. New CT findings of response and recurrence independent of change in tumor size in colorectal liver metastasis treated with Bevacizumab. Radiological Society of North America, 2011. e-Pub 2011.
67. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. Journal of Clinical Oncology 28:3592, 2010. e-Pub 2010.
68. Chang G, Maru DM, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. 12th World Congress on Gastrointestinal Cancer, 2010. e-Pub 2010.
69. Chang G, Maru DM, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. Annals of Oncology, 2010. e-Pub 2010.
70. Tran B, Kopetz S, Jeanne T, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Distinct differences in sites of metastatic disease may contribute to poorer outcomes observed in patients with BRAF mutant colorectal cancers. American Society of Clinical Oncology Annual Meeting, 2010. e-Pub 2010.
71. Tran B, Kopetz S, Jeanne T, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Distinct Differences in Sites of Metastatic Disease May Contribute to Poorer Outcomes Observed in Patients with BRAF Mutant Colorectal Cancers. American Society of Clinical Oncology Annual Meeting, 2010. e-Pub 2010.
72. Agarwal A, Seth S, Lin E, Lutheran R, Rashid A, Hamilton SR, Eng C, Maru DM. Histological subtypes of microsatellite instability-high (MSI-H) colorectal adenocarcinoma (CRCs) and their association with clinic pathologic features and prognosis. United States and Canadian Academy of Pathology, Washington, D.C, 2010. e-Pub 2010.
73. Agarwal A, Lopez S, Boonsirikamchai P, Chun YS, Wang H, Vauthey JN, Loyer EM, Maru DM. Tumor thickness at tumor-normal interface (TNI): A novel pathologic indicator of chemotherapy response in hepatic colorectal metastases (HCRM). United States and Canadian Academy of Pathology, Washington, D.C, 2010. e-Pub 2010.
74. Agarwal A, Kopetz S, Boonsirikamchai P, Chun YS, Wang H, Vauthey JN, Loyer EM, Maru DM. Tumor thickness at Tumor-Normal Interface (TNI): A novel pathologic indicator of chemotherapy response in Hepatic Colorectal Metastases (HCRM). United States and Canadian Academy of Pathology, 2010. e-Pub 2010.
75. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. Journal of Clinical Oncology 28, 2010. e-Pub 2010.
76. Boonsirikamchai P, Maru DM, Chun YS, Kaur H, Kopetz S, Loyer EM. New CT findings of response and recurrence independent of change in tumor size in colorectal liver metastasis treated with Bevacizumab. 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Chicago, 2009. e-Pub 2009.
77. Goodarzi M, Rashid A, Maru D. Anti-phosphohistone H3 shows differential expression in Barrett's esophagus, low grade, high grade dysplasia, adenocarcinoma sequence. United States and Canadian Academy of Pathology, 2009. e-Pub 2009.
78. Maru DM, Correa AM, Tong Z, Wang H, Wu TT, Corley L, Krishnan S, Ajani JA, Swisher S, Rashid A, Hofstetter W, Guha S. Loss of neutrophil gelatinase associated lipocalin (NGAL) expression in esophageal adenocarcinoma (EAC) is associated with higher pathologic stage and poor survival. United States and Canadian Academy of Pathology, 2009. e-Pub 2009.
79. Bolton W, Hofstetter W, Francis A, Correa A, Ajani J, Bhutani M, Erasmus J, Komaki R, Maru D, Mehran R, Rice D, Roth J, Vaporciyan A, Walsh G, Swisher SG. Impact of tumor length and submucosal involvement on the long-term survival of pT1 early stage esophageal adenocarcinoma. American Association of Thoracic Surgery, San Diego, CA, 2008. e-Pub 2008.
80. Fukami N, Dekovich A, Matthew R, Maru D, Wang H, Hofstetter WL. Multifocal high-grade dysplasia (MFHGD) in Barrett's esophagus is associated with adenocarcinoma in patients undergoing endoscopic mucosal resection (EMR) for Barrett's esophagus. Digestive Disease Week, San Diego, CA, 2008. e-Pub 2008.
81. Thekkek N, Maru D, Anandasabapathy A, Richards-Kortum R. Developing optical biomarkers to characterize the progression of Barrett's esophagus to pre-cancer author block. Biomedical Optics Topical Meeting (BIOMED), Tampa, FL, 2008. e-Pub 2008.
82. Cen P, Correa AM, Lee JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's or without Barrett’s: Differences in patients survival after preoperative chemoradiation. American Society of Clinical Oncology Annual Meeting, 2008. e-Pub 2008.
83. Maru DM, Luthra R, White-Cross J, Singh R, Rashid A. Frequent loss of heterozygosity (LOH) of chromosome 1q in esophageal adenocarcinoma. United States and Canadian Academy of Pathology (USCAP), Modern Pathology, Denver 21, 2008. e-Pub 2008.
84. Maru DM, Khurana H, Correa AM, Swisher SG, Ajani JA, Rashid A. Clinicopathiologic features and prognosis of high-grade neuroendocrine carcinoma of esophagus. United States and Canadian Academy of Pathology, Modern Pathology, Denver 21, 2008. e-Pub 2008.
85. Taggart MW, Wang H, Maru D, Tan D, Rashid A. Appendiceal mixed carcinoid-adenocarinomas share better prognosis associated with goblet cell carcinoid tumors. United States and Canadian Academy of Pathology, Denver 21, 2008. e-Pub 2008.
86. Tetzlaff ED, Correa AM, Komaki R, Swisher S, Maru D, Ross W, Ajani JA. The significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. ISGIO, 2007. e-Pub 2007.
87. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. ISGIO, 2007. e-Pub 2007.
88. Dave B, Mahajan A, Maru D. Alk-1 expression in extranodal anaplastic large cell lymphoma-experience at a tertiary cancer center in India. United States and Canadian Academy of Pathology, Atlanta, 2006. e-Pub 2006.
89. Prabash K, Nair R, Biswas G, Bakshi A, Gupta S, Prasad N, Maru D, Laskar S, Parikh P. Primary thyroid lymphoma-an experience from single center. Annals of Oncology 17:185, 2006. e-Pub 2006.
90. Troffe J, Roy-Chaudhury P, Gordon J, Wadih G, Maru D, Cardi M, Alloway R, Khalili K, Woodle E. ITSCO4-viral load monitoring in patients with polyomavirus, who have been treated for rejection episodes. International Transplantation Society, 2004. e-Pub 2004.
91. Trofe J, Gordon J, Khalili K, Maru D, Munda R, Woodle E, Roy-Chaudhury P. Histologic grading of PVN biopsies: Correlation with viral load monitoring and renal function. American Transplant Congress, Boston, 2004. e-Pub 2004.
92. Maru D, Wang S, Middleton L, Valero V, Sahin A. Biomarkers of breast carcinoma occuring in women younger than 30 yrs. United States and Canadian Academy of Pathology, Washington, DC, 2003. e-Pub 2003.
93. Chester-Pacheco C, Maru D, Fenoglio-Preiser C. Laser scanning confocal microscopic appearance of upper gastrointestinal lesions. United States and Canadian Academy of Pathology, 2003. e-Pub 2003.
94. Maru D, Wu T, Canada A, Houlihan P, Cleary K, Hamilton S, Rashid A. Frequent loss of chromosome 18q and DPC4 mutations in mucinous and non-mucinous appendiceal adenocarinomas. United States and Canadian Academy of Pathology, Washington, DC, 2003. e-Pub 2003.
95. Maru D, Somogyi L, Robinson-Smith T, Yassin R. Endoscopic ultrasound guided fine needle aspiration of pancreatic and peripancreatic lesions. International Congress of Cytology, Amsterdam, Netherlands, 2001. e-Pub 2001.
96. Saad A, Maru D, Yassin R. Fine needle aspiration of angiomatoid fibrous histiocytoma of skin. International Congress of Cytology, Amsterdam, Netherlands, 2001. e-Pub 2001.
97. Liao J, Maru D, Cualing H. Flow cytometric evaluation of CD71 expression in Follicular Center Cell Lymphoma. United States and Canadian Academy of Pathology, 2001. e-Pub 2001.
98. Yassin R, Cualing H, Maru D, Smith R, Hurtubise P. Color image segmentation of tumor infiltrating lymphocytes. United States and Canadian Academy of Pathology, Atlanta, 2001. e-Pub 2001.
99. Maru D, Feboglio-Preiser C, Stemmermman G. Prognostic significance of Crohn's like and T-suppressor host response patients with adenocarcinoma of colon. United States and Canadian Academy of Pathology, Atlanta, 2001. e-Pub 2001.
100. Miles L, Cualing H, Hurtubise P, Maru D. Morphometric and flow cytometric findings in repopulating and regenerating bone marrow. United States and Canadian Academy of Pathology, Atlanta, 2001. e-Pub 2001.
101. Maru D, Wilbowo J, Cualing H. Chronic and blastic phases of chronic myeloid leukemia show differential levels of murine double minute 2 (MDM 2). United States and Canadian Academy of Pathology, Atlanta, 2001. e-Pub 2001.

Book Chapters

1. Maru, DM. Pathological Response Criteria, 441-445, 2022.
2. Maru DM. Histopathologic evaluation and neoadjuvant treatment response and tumor regression grade. In: Rectal Cancer:Modern Approaches to Treatment. Springer, 2017.
3. Maru DM. How will histopathology affect the management of the multidisciplinary team?. In: Colorectal Cancer: Diagnosis and Management. Wiley-Blackwell, 2013.
4. Contreras CM, Brouquet A, Maru DM, J-N AV. Hepatic steatosis, steatohepatitis, and chemotherapy-related liver injury. In: Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas. 5th. Elsevier-Health Sciences Division, 999-1005, 2011.
5. Maru DM, Fenoglio-Preiser C. AIDS related gastrointestinal diseases. In: AFIP Fascicle for Non- neoplastic Gastrointestinal Diseases. American Registry of Pathology, 2007.
6. Maru DM. Malabsorption syndrome. In: AFIP Fascicle for Non-neoplastic Gastrointestinal Diseases. American Registry of Pathology, 2007.
7. Maru DM. Ischemic bowel diseases. In: AFIP Fascicle for Non-neoplastic Gastrointestinal Diseases. American Registry of Pathology, 2007.
8. Maru DM, Fenoglio-Preiser C. Benign gastric diseases. In: AFIP Fascicle for Non- neoplastic Gastrointestinal Diseases. American Registry of Pathology, 2007.
9. Maru D. Pathological Response Criteria. In: Colorectal Liver Metastasis. Springer Nature.

Books (edited and written)

1. Noffsinger A, Fanoglio-Preiser C, Maru DM, Gillinsky N. Armed Forces Institute of Pathology, Atlas of Non-tumor Pathology of Gastrointestinal Disease. American Registry of Pathology, 2007.

Patents

1. Colorectal Cancer Consensus Molecular Subtype Classifier Codesets And Methods Of Use Thereof. Patent Number: USSN 62/828,098.